Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Wednesday, 08 / 04 / 2021

Articles

Abstract

ORIGINAL ARTICLE

Tenofovir Alafenamide Fumarate, Tenofovir Disoproxil Fumarate and Entecavir: Which is the Most Effective Drug for Chronic Hepatitis B? A Systematic Review and Meta-analysis

Xuefeng Ma1,#, Shousheng Liu2,3,#, Mengke Wang1, Yifen Wang1, Shuixian Du1, Yongning Xin1,3,*and Shiying Xuan1,3,*

1  Department of Infectious Disease, Qingdao Municipal Hospital, Qingdao University, Qingdao, Shandong, China
2  Clinical Research Center, Qingdao Municipal Hospital, Qingdao University, Qingdao, Shandong, China
3  Digestive Disease Key Laboratory of Qingdao, Qingdao, Shandong, China
#Both authors contributed equally to this work.
*Correspondence to: Yongning Xin, Department of Infectious Disease, Qingdao Municipal Hospital, 1 Jiaozhou Road, Qingdao, Shandong 266011, China. ORCID:  https://orcid.org/0000-0002-3692-7655 . Tel: +86-532-8278-9463, Fax: +86-532-8596-8434, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. ; Shiying Xuan, Department of Infectious Disease, Qingdao Municipal Hospital, 1 Jiaozhou Road, Qingdao, Shandong 266011, China. ORCID:https://orcid.org/0000-0002-9849-1877 . Tel: +86-532-8890-5508, Fax: +86-532-8890-5293, E-mail:This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2021;9(3):335-344 DOI: 10.14218/JCTH.2020.00164
Received: December 14, 2020 Accepted: March 9, 2021 Published online: March 29, 2021

Abstract

Background and Aims:The therapeutic effect of tenofovir alafenamide fumarate (TAF), tenofovir disoproxil fumarate (TDF) and entecavir (ETV) on chronic hepatitis B (CHB) patients remains inconsistent. The aim of this study was to explore the differences in virological responses to TAF, TDF and ETV in patients with CHB.

Methods: Literature searches were conducted of the PubMed, EMBASE, and the Cochrane Library databases to identify randomized controlled trials and observational studies published up to July 21, 2020. Statistical comparisons of virological response between TDF, ETV, and TAF were carried out with pooled odds ratio (OR) values.

Results:The virological response in TDF-treated CHB patients was notably superior to that of the ETV-treated CHB patients after 12-weeks [OR=1.12, 95% confidence interval (CI): 0.89–1.41], 24-weeks (OR=1.33, 95% CI: 1.11–1.61), 48-weeks (OR=1.62, 95% CI: 1.16–2.25), 72-weeks (OR=1.43, 95% CI: 0.78–2.62), and 96-weeks (OR=1.56, 95% CI: 0.87–2.81) treatment. No significant difference was observed for the virological responses in CHB patients after 48-weeks treatment with TAF or TDF. The virological response in TDF+ETV-treated CHB patients was superior to that of TDF-treated CHB patients after 24-weeks, 48-weeks (OR=1.54, 95% CI: 1.17–2.02), 96-weeks, and 144-weeks.

Conclusions:The virological response in TDF-treated CHB patients was superior to that in ETV-treated CHB patients, but there was no significant difference between TAF and TDF. In addition, the therapeutic effect of TDF+ETV was superior to TDF alone.

Keywords

Tenofovir alafenamide, Entecavir, Tenofovir disoprox, Chronic hepatitis B, Virological response

Journal of Clinical and Translational Hepatology 2021 vol. 9, 335-344  [ Html  ] [ PDF Full-text ]

© 2021 Authors. This is an Open Access article distributed under the terms of the  Creative Commons Attribution-Noncommercial 4.0 License(CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

 logo

You are here: Home